Examining how immune-inflammatory biomarkers affect PTSD treatment response
The Predictive Role of Immune-inflammatory Biomarkers and Their Interaction With the Oxytocin System in Trauma-related Psychotherapy Responsiveness
This study is trying to see how certain biological markers in the body affect how well people with PTSD respond to therapy over 12 weeks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Shalvata Mental Health Center Academic / other |
| Locations | 1 site (Hod HaSharon) |
| Trial ID | NCT06348472 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of immune-inflammatory biomarkers and their interaction with the oxytocin system in influencing treatment responsiveness in patients with posttraumatic stress disorder (PTSD). It aims to recruit 100 participants from the Shalvata Mental Health Center who will undergo psychotherapy for 12 weeks. The study will assess how these biological factors may impact the development of PTSD and the effectiveness of psychotherapy. By understanding these interactions, the research seeks to identify predictors of treatment outcomes for PTSD patients.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with PTSD symptoms who have a minimum score of 33 on the PTSD symptoms questionnaire and are expected to undergo 12-24 psychotherapy sessions.
Not a fit: Patients experiencing a psychotic episode or female patients who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with PTSD.
How similar studies have performed: While the specific interaction of immune-inflammatory biomarkers and the oxytocin system in PTSD treatment is relatively novel, related studies have shown promise in understanding biological factors influencing treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Minimum score of 33 on the PTSD symptoms questionnaire (PCL-5). * Anticipated 12-24 psychotherapy sessions. Exclusion Criteria: * Psychotic episode. * Female patients: pregnancy or breastfeeding (according to self-report).
Where this trial is running
Hod HaSharon
- Shalvata Mental health Center — Hod HaSharon, Israel (Recruiting)
Study contacts
- Study coordinator: Omer Sedoff, MA
- Email: omerse@clalit.org.il
- Phone: 97297478555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.